Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S
/PRNewswire/ -- Paradigm Biopharmaceuticals (ASX: PAR) a global biopharmaceutical company driven to improve patients' lives through repurposing existing drugs...
Source: prnewswire.com